TABLE 2.
Cohort Characteristics
| Hospitalized (n = 1152)
|
Nonhospitalized (n = 333)
|
|||||
|---|---|---|---|---|---|---|
| Characteristic | M | (SD) | Range | M | (SD) | Range |
| Age at diagnosis (yrs) | 77.3 | (5.0) | 66–97 | 78.9 | (5.7) | 66–97 |
| Educationa | 19.9 | (13.4) | 0–68.8 | 19.0 | (13.0) | 0.71–71.7 |
| n | %b | n | %b | |||
| Sex (female) | 647 | (56.2) | 132 | (39.6) | ||
| Comorbidity scorec | ||||||
| 0 | 477 | (41.4) | 198 | (59.5) | ||
| 1 | 300 | (26.0) | 83 | (24.9) | ||
| 2 | 197 | (17.1) | 33 | (9.9) | ||
| ≥3 | 178 | (15.4) | 19 | (5.70) | ||
| Range (pre-recode) | 0–9 | 0–5 | ||||
| Married (yes) | 630 | (54.7) | 176 | (52.9) | ||
| Urbanization | ||||||
| Big metro | 618 | (53.7) | 181 | (54.4) | ||
| Metro/urban | 386 | (33.5) | 126 | (37.8) | ||
| Less urban/rural | 147 | (12.8) | 26 | (7.8) | ||
| SEER Registry Region | ||||||
| New Jersey | 249 | (21.6) | 79 | (23.7) | ||
| Westd | 317 | (27.5) | 114 | (34.2) | ||
| Southe | 262 | (22.7) | 60 | (18.0) | ||
| Mid/Northeastf | 324 | (28.1) | 80 | (24.0) | ||
| Race (White) | 1025 | (89.0) | 289 | (87.0) | ||
| Incomeg | 45333 | 7–200008 | 45857 | 7887–200008 | ||
| Disease stage | ||||||
| 0 | 4 | (0.4) | 27 | (8.1) | ||
| I | 101 | (8.8) | 102 | (30.6) | ||
| II | 294 | (25.5) | 43 | (12.9) | ||
| III | 658 | (57.1) | 67 | (20.1) | ||
| Unknownh | 95 | (8.3) | 94 | (28.2) | ||
| Radiation treatment | ||||||
| External beam | 280 | (24.8) | 100 | (30.6) | ||
| Nonei | 849 | (75.2) | 227 | (69.4) | ||
| Chemotherapyj | ||||||
| 5-Fluorouracil | 1010 | (87.7) | 166 | (49.9) | ||
| Oxaliplatin | 586 | (50.9) | 61 | (18.3) | ||
| MAbs | 439 | (38.1) | 62 | (18.6) | ||
| Irinotecan | 295 | (25.6) | 23 | (6.9) | ||
Note. MAbs = monoclonal antibodies.
a
Census tract percentage of non-high school graduates.
b
Percentages based on column totals.
c
NCI Combined Index.
d
California, Hawaii, Seattle.
e
Kentucky, Louisiana, Georgia.
f
Michigan, Connecticut, Iowa, New Mexico, Utah.
g
Census tract median income.
h
Not missing.
i
Includes refused.
j
Patients generally received more than one drug class during the study period.